Year: 2024 | Month: January-March | Volume: 9 | Issue: 1 | Pages: 138-147
DOI: https://doi.org/10.52403/gijhsr.20240115
Genomics and Drug Research Approach in Identifying Potential Drug Target Highlighting Alzheimer Disease
Anupriya1,2, Ayushi Poddar1,2, Sneha Priya1,3, Priyangulta Beck1, Harsimran Kaur1,4, Seema Kumari1,6, Barkha Kachhap1,6, Nisha Rani Soreng1,2, Swati Shalika1,6, Mukesh Nitin1
1Department of Tech. Biosciences, Digianalix, South Samaj Street, Tharpakhna, Ranchi, Jharkhand, INDIA.
2Department of Biotechnology, Gossner College, Ranchi, Jharkhand, INDIA.
3Department of Biotechnology, Ranchi Women’s College, Ranchi, Jharkhand, INDIA.
4School of Biotechnology, Devi Ahilya Vishwavidyalaya, Indore, INDIA.
5University Department of Botany, Ranchi University, Ranchi, Jharkhand, INDIA.
6Department of Biotechnology, Marwari College, Ranchi, Jharkhand, INDIA.
Corresponding Author: Dr. Mukesh Nitin
ABSTRACT
Over the past few years research on alzheimer’s disease (AD) has been grown experimentally which is a neurodegenerative disease and the most common form of dementia that cause memory loss and affect the ability to think which can interfere with daily life. The main cause of AD is on the growth of plagues and tangles. AD is most commonly found in the age of 60s, starts with mild memory loss and other disabilities which lead the person to forget things on their daily life. In our research we are trying to identify potential natural based bioactive drug source compound using advanced computational biology to help in exploring clues for the treatment of AD patients using molecular docking method. BACE1 was screened as a potential target receptor in our study for the disease research. We also observed chromen-4-one as potent bioactive compound presenting high docking score of -5.60 Kcal/mol against BACE1 followed by other compounds. This identification will open new scope to future researchers to explore more bioactive compounds which may aid new treatment options against AD followed with wet lab experimentation.
Keywords: APP (Amyloid Precursor Protein), BACE1, Alzheimer disease, Neurodegenerative, Molecular docking, Hydrophobicity